Intriguingly, high expression of DHODH, a rate-limiting step in de novo pyrimidine synthesis, was adversely prognostic in patients with IDH mutant GBM, which suggests that further investigation of pyrimidine biosynthesis could be interesting in gliomas with an IDH mutation. The gene discussed is IDH1; the disease is glioblastoma.